KNSA Q2 record revenue growth; 2026 guidance increased
Q2 delivered record revenue growth and the company increased 2026 guidance. ARCALYST reached 21% penetration in its core patient group, while pipeline assets including KPL-387 advanced.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.